BioLineRx Secures $5.6 Million Funding through Royalty Monetization Deal

BioLineRx's Recent Royalty Monetization Agreement



BioLineRx Ltd. (NASDAQ: BLRX) has successfully entered into a $5.6 million royalty monetization strategy in collaboration with Soleus Capital Management, L.P. This strategic financial move enables the clinical-stage biopharmaceutical company to secure necessary funds without diluting existing shareholder value. The transaction specifically involves BioLineRx's share of future royalties from the drug APHEXDA (motixafortide), a significant therapy in their portfolio intended for oncology and rare diseases.

Details of the Agreement


The one-time payment will grant Soleus Capital a 14.4% interest in future royalties stemming from the sales of APHEXDA under a licensing agreement established with Ayrmid Pharma Ltd. However, it is crucial to note that the deal does not include an additional 3.6% royalty interest, which remains with the original licensor of the drug to BioLineRx. Despite the transaction, BioLineRx continues to hold rights to future milestone payments related to commercialization and retains earnings for royalty periods before the agreement’s closing.

Philip Serlin, the CEO of BioLineRx, expressed optimism about the transaction, stating that it provides an immediate financial boost to the company. He emphasized that the capital will allow for continued advancement in the clinical development of their lead asset, GLIX1, which is currently undergoing a Phase 1/2a clinical trial for glioblastoma and other significant solid tumors.

Financial Utilization


The proceeds from this transaction are earmarked primarily for the ongoing research and development efforts concerning GLIX1, while also addressing general corporate needs. Notably, part of the funds will be allocated towards repaying a loan from BlackRock EMEA Venture and Growth Lending, resulting in an elimination of the existing cash balance requirement mandated by the loan agreement, which currently stands at $4 million. The completion of the deal is slated for around November 30, 2026.

Insights on APHEXDA


APHEXDA is recognized as a CXCR4 antagonist and has received FDA approval to enhance stem cell mobilization for patients diagnosed with multiple myeloma, facilitating the collection of hematopoietic stem cells for subsequent autologous transplantation. This innovative treatment option is being marketed globally, with Ayrmid holding rights outside of Asia—where Gloria Biosciences is the partner.

About BioLineRx and Soleus Capital


BioLineRx is devoted to developing transformative therapies targeted at oncology and rare diseases, with a focus on innovative solutions like GLIX1, which aims to tackle DNA damage response mechanisms. Soleus Capital, based in Greenwich, CT, is an investment firm that specializes in life sciences, possessing approximately $3.5 billion in total assets under management as of June 30, 2026.

The collaboration with Soleus Capital reflects an ongoing trend among biopharmaceutical firms seeking creative financing solutions that do not compromise equity. As BioLineRx moves forward, this transaction stands as a testament to its commitment to advancing its clinical trials and bringing impactful therapies to market for patients worldwide.

Stay tuned for further updates on BioLineRx's progress and the ongoing developments surrounding GLIX1 and APHEXDA.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.